Investors

Overview

Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company owns a significant intellectual property (IP) portfolio related to DMF formulations. The Company granted to Biogen an irrevocable license to all of its IP through the recent License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 opposition proceeding.


Most Recent Presentation
Download Documentation Deutsche Bank Healthcare Conference

Stock Information
FWP (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Financial Status IndicatorC
Price$19.47
Change (%) Stock is Down 0.22 (1.12%)
Volume3,642
Data as of 05/26/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock chart for: FWP.OQ.  Currently trading at $19.47 with a 52 week high of $32.70 and a 52 week low of $14.89.

Recent NewsMore >>
DateTitle 
05/01/17Forward Pharma CEO to Present at the 42nd Annual Deutsche Bank Health Care Conference on May 4, 2017
COPENHAGEN, Denmark, May 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference, being held May 3-4, 2017 in Boston, MA. Dr. Svendsen will present on Thursday, May 4, at 10:40 AM ET and host one-on-one meetings before and after the presentation. Investors and other interested parties may access a live audio webcast of our... 
Printer Friendly Version
05/01/17Forward Pharma Further Aligns Cost Structure with Focus Following Settlement and License Agreement
COPENHAGEN, Denmark, May 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”) today provided an update on the Company’s strategic focus and related initiatives to reduce operating and personnel costs following the Settlement and License Agreement with Biogen. Consistent with the focus on executing on the intellectual property strategy and the planned timeline for conclusion of ongoing research and development activities, Executive Vice Presidents R... 
Printer Friendly Version
04/18/17Forward Pharma Reports Fourth Quarter and Year End 2016 Financial and Operational Results
COPENHAGEN, Denmark, April 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”), today reported financial results for the fourth quarter and year ended December 31, 2016. Net income for the fourth quarter December 31, 2016 was $9.6 million while net loss for the year ended December 31, 2016 was $33.3 million, or $0.20 and $(0.71) per diluted share, respectively. On a non-GAAP basis, after removing the effect of non-cash income and expense items, our... 
Printer Friendly Version
03/31/17Forward Pharma Intends to Appeal Decision in Patent Interference Proceeding with Biogen Inc.
COPENHAGEN, Denmark, March 31, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (FWP) (“Forward Pharma” or the “Company”), a biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that it intends to file an appeal challenging today’s decision by the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”) in Pat... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
06/06/17 3:00 p.m. ET
Forward Pharma A/S at Jefferies 2017 Global Healthcare Conference
LocationNew York, NY
06/20/17 3:30 p.m. ET
Forward Pharma A/S at JMP Securities Life Sciences Conference
LocationNew York, NY
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Forward Pharma A/S posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources